Yahoo
NYSE USD

Abbott Laboratories (ABT)

108.33 -0.46 (-0.42%)
At close: September 4 at 4:04:03 PM EDT
108.43 +0.10 (+0.09%)
After hours: September 4 at 7:57:15 PM EDT
Trade ABT on Coinbase
Chart Range Bar
Loading chart for ABT

What's happening with ABT?

10m ago
Powered by Yahoo Scout

Abbott Laboratories (ABT) is facing challenges with a 19.7% declinefrom its 52-week high, attributed to weaker demand in key sectors. Despite these struggles, a consensus of 29 analystsmaintains a 'Strong Buy'rating, with a price target of $121.33.

Powered by Yahoo Scout
  • Previous Close 108.79
  • Open 108.11
  • Bid 107.35 x 30000
  • Ask 108.30 x 30000
  • Day's Range 107.36 - 110.01
  • 52 Week Range 81.97 - 137.49
  • Volume 6,880,590
  • Avg. Volume 11,298,032
  • Market Cap (intraday) 187.452B
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) 35.06
  • EPS (TTM) 3.09
  • Earnings Date Oct 14, 2026
  • Forward Dividend & Yield 2.52 (2.32%)
  • Ex-Dividend Date Jul 15, 2026
  • 1y Target Est 120.20

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

www.abbott.com

122,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABT
11.93%
S&P 500 (^GSPC)
12.75%

1-Year Return

ABT
16.55%
S&P 500 (^GSPC)
18.71%

3-Year Return

ABT
12.12%
S&P 500 (^GSPC)
70.93%

5-Year Return

ABT
7.40%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Analyst Insights

View More

Analyst Price Targets

103.00 Low
120.20 Average
108.33 Current
135.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/25/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 115 -> 135

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.65%

  • Return on Assets (ttm)

    5.33%

  • Return on Equity (ttm)

    10.58%

  • Revenue (ttm)

    46.58B

  • Net Income Avi to Common (ttm)

    5.4B

  • Diluted EPS (ttm)

    3.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.6B

  • Total Debt/Equity (mrq)

    63.21%

  • Levered Free Cash Flow (ttm)

    7.21B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: